ARCTURUS THERAPEUTICS HOLDINGS INC. Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) reported Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions of $925.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions · last filed 2026-03-03
- ARCTURUS THERAPEUTICS HOLDINGS INC. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2025 was $925.00K, a 52.56% decline from fiscal 2024.
- ARCTURUS THERAPEUTICS HOLDINGS INC. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2024 was $1.95M, a 225.00% increase from fiscal 2023.
- ARCTURUS THERAPEUTICS HOLDINGS INC. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2023 was $600.00K, a 40.00% decline from fiscal 2022.
- ARCTURUS THERAPEUTICS HOLDINGS INC. unrecognized tax benefits, increase resulting from current period tax positions for fiscal 2022 was $1.00M, a 0.00% change from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions 12 month | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions 12 month as first filed |
|---|---|---|
| 2025-12-31 | $925.00K 10-K · filed 2026-03-03 | |
| 2024-12-31 | $1.95M 10-K · filed 2026-03-03 | $2.00M 10-K · filed 2025-03-06 |
| 2023-12-31 | $600.00K 10-K · filed 2025-03-06 | |
| 2022-12-31 | $1.00M 10-K · filed 2024-03-14 | |
| 2021-12-31 | $1.00M 10-K · filed 2023-03-29 | |
| 2020-12-31 | $800.00K 10-K · filed 2022-03-01 | |
| 2019-12-31 | $0.00 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |